T Cell Receptors Targeting HPV 6 or HPV 11
Summary:
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a collection of T cell receptors (TCRs) that specifically target HPV 6 or HPV 11 antigens.
Use of Acetalax for Treatment of Triple Negative Breast Cancer
Summary:
NCI seeks research co-development and/or potential licensees for a potential novel treatment for triple-negative breast cancer (TNBC) with acetalax (oxyphenisatin acetate).
C8166-45 and C8166 Cells
Summary:
The National Cancer Institute (NCI) seeks licensees for human T-cell lines, C8166 and C8166-45, transformed by HTLV-1. C8166-45, a subclone of C8166, contains three transcriptionally active proviruses useful for testing biological activities involved in T-cell immortalization and growth.
Bifunctional Antibody Fusion Molecules for Use in Cancer Immunotherapy
Summary:
The National Cancer Institute is seeking research co-development partners and licensing collaborators to accelerate the development and commercialization of innovative bifunctional antibody fusion molecules designed to activate and expand engineered TCR-expressing cells, advancing next-generation cancer immunotherapies.
Synergistic Use of Exo VII Inhibitors And Quinolone Antibiotics For Treating Bacterial Infection
Summary:
The National Cancer Institute (NCI) seeks licensees to further develop novel exonuclease VII (ExoVII) inhibitors as antibiotic adjuvants for enhancing the efficacy of quinolone antibiotics, particularly in quinolone-resistant bacterial infection.
NeoExpansion – A Method to Identify and Selectively Expand Neoantigen-specific T Cells, Including T Cell Receptor-engineered T Cells and Tumor Infiltrating Lymphocytes
Summary:
The National Cancer Institute (NCI) seeks co-development partners and/or licensees for a method of identifying and selectively expanding neoantigen-specific T cells.
Small Molecule Anti-cancer Agents that Stabilize the MYC-G-Quadruplex
The proto-oncogene c-Myc is deregulated and overexpressed in ~70% of all cancers. Thus, c-Myc is an attractive therapeutic target since disrupting c-Myc activity could be used as pan-chemotherapy. Beyond cancer, Myc is also a positive effector of tissue inflammation, and its function has been implicated in the pathophysiology of heart failure. Because c-Myc is a transcription factor, a rationally designed small molecule targeting c-Myc would be required to exhibit significant specificity.
Bispecific Antibodies: A Novel Approach to Treating Ebola Virus Infections
The described technology pertains to the development of bispecific antibodies targeting the Ebola virus glycoprotein. These antibodies, mAb114 and either S1-4-A09 or its engineered variant S1-4-A09 A80P, demonstrate specificity towards the Ebola virus (EBOV) glycoproteins from different strains, including Kikwit and Bundibugyo. The variant S1-4-A09 A80P retains binding specificity and activity but lacks a glycosylation motif, enhancing manufacturability without compromising function.
Nucleophosmin 1 (NPM1) Mutation-Specific T Cell Receptors for Targeted Treatment of Acute Myeloid Leukemia
Summary:
The NCI seeks research co-development partners or licensees for Nucleophosmin 1 (NPM1) Mutation-Specific T Cell Receptors for Targeted Treatment of Acute Myeloid Leukemia.
Drug-Regulatable, Inducible Expression of Membrane-Bound Interleukin 12 (DRIM-IL-12) for Use in Adoptive Cell Therapy
Summary:
Scientists at the National Cancer Institute (NCI) have developed a novel tightly regulated drug-responsive, membrane-bound IL-12 cytokine platform, that enhances anti-tumor efficacy in adoptive cell therapy (ACT) with engineered T-cells (CAR, TCR, TILs) while improving safety. The NCI seeks research co-development partners and/or licensees to advance this technology toward clinical translation.